Piperacillin-tazobactam removal during kidney replacement therapy in ICU
Part of Infections clinical trials.
This study looks at how well a continuous kidney replacement therapy removes a common antibiotic combination (piperacillin and tazobactam) from the blood in intensive care patients. It may help doctors better dose the antibiotic for patients on this type of dialysis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are admitted to the intensive care unit (ICU)
- You are receiving a specific type of continuous kidney replacement therapy (CVVH, CVVHD, or CVVHDF) for kidney failure
- You have a known or suspected infection that is treated with piperacillin-tazobactam, given as a continuous infusion
- You are prescribed both the antibiotic and the kidney replacement therapy at the same time
- You are covered by health insurance and can agree to take part (or a family member can agree for you if you are too ill)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two antibiotics—piperacillin-tazobactam or temocillin—to treat severe ICU infections caused by certain hard-to-treat gut bacteria (ESBL). It may help patients avoid the use of carbapenem antibiotics like meropenem when the bacteria are susceptible.
This study watches how safely two common antibiotics (vancomycin and a combination called piperacillin/tazobactam) work together in hospitalized patients with serious infections. Researchers want to make sure the combination doesn't harm kidney function.
This trial tests whether giving a certain type of antibiotic (beta-lactam) continuously or intermittently works better for patients in the intensive care unit with pneumonia or a urinary tract infection and signs of sepsis. Sepsis is a serious response to an infection, so better antibiotic delivery could improve outcomes.
This trial compares giving a long, continuous infusion versus standard short infusions of certain antibiotics (beta-lactams) to children with sepsis in intensive care. The goal is to find which method works better and is safer.
This trial compares two common antibiotics, meropenem and piperacillin/tazobactam, to see which works better for adults with sepsis who are critically ill. It aims to help doctors choose the best treatment for serious infections.
This trial studies how much certain antibiotics (meropenem, linezolid, and daptomycin) are removed when you're on a special blood-filtering machine called continuous renal replacement therapy (CRRT) for severe kidney injury. The results could help doctors give the right dose of antibiotics to treat infections effectively.
Hear when a new Sepsis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.